This single-center noninferiority randomized clinical trial enrolled 80 adult postoperative cancer patients requiring mechanical ventilation in the ICU. Patients received either remimazolam or propofol for sedation. The primary outcomes of time to achieve target sedation (RASS -2 to 0) and percentage of time within target range were comparable between groups. Time to target sedation was a median of 3.0 minutes for both remimazolam (IQR 2.0–4.0) and propofol (IQR 2.0–4.5), with P = 0.590. The percentage of time within target range was median 80.0% for remimazolam versus 73.2% for propofol (P = 0.546).
Regarding safety, remimazolam demonstrated a significantly lower incidence of hypotension (15.0% vs 42.5%, P = 0.007) and respiratory depression (5.0% vs 20.0%, P = 0.043) compared to propofol. Adverse events, serious adverse events, and discontinuation rates were not reported. Secondary outcomes including duration of mechanical ventilation, ICU length of stay, mortality, and costs showed no significant differences, though specific data were not provided.
Key limitations include the single-center design and small sample size. The study does not report on long-term outcomes, mortality differences, or detailed cost-effectiveness. Follow-up duration was not reported. While the trial suggests remimazolam may offer a hemodynamic and respiratory safety advantage over propofol for short-term sedation in this specific postoperative cancer population, these findings require validation in larger, multicenter studies before broader clinical adoption.
Waking up from major cancer surgery on a breathing machine is a critical and stressful time. Doctors need a sedative that keeps patients calm and comfortable without causing dangerous side effects. A new study compared two drugs for this purpose in 80 cancer surgery patients: the standard propofol and a newer option called remimazolam.
The study found remimazolam worked just as quickly and effectively to achieve the right level of calm. The key difference was safety. Patients getting remimazolam were much less likely to experience a dangerous drop in blood pressure or have their breathing slow down too much—common and risky problems with the standard drug.
This is promising news for a group of patients who are often very fragile. However, it's important to remember this was a relatively small study at just one hospital's intensive care unit. The researchers didn't find any differences in how long patients needed the breathing machine, their total ICU stay, or survival rates. More research in larger, more diverse groups is needed to confirm these safety benefits.
What this means for you: A newer sedative worked as well as the standard but with fewer dangerous side effects for vulnerable cancer surgery patients.
View Original Abstract ↓
ObjectiveThis study aimed to compare the efficacy and safety of the novel ultra-short-acting benzodiazepine, remimazolam, versus propofol for short-term sedation in postoperative cancer patients during mechanical ventilation in the ICU.MethodsThis single-center, randomized noninferiority clinical trial was conducted from February 1st to 31 August 2024. Adult postoperative cancer patients requiring mechanical ventilation in the ICU were randomized to receive either remimazolam or propofol. The primary outcomes were the time to achieve target sedation (Richmond Agitation-Sedation Scale, RASS, −2 to 0) and the percentage of time within the target range without rescue sedation.ResultsA total of 80 patients were enrolled and randomly assigned to the remimazolam group (n = 40) or the propofol group (n = 40). The time to achieve target sedation was comparable between the remimazolam and propofol groups [median 3.0 (IQR 2.0–4.0) vs. 3.0 (IQR 2.0–4.5) minutes, P = 0.590]. The median percentage of time within the target sedation range was also similar (80.0% vs. 73.2%, P = 0.546). However, remimazolam demonstrated a superior safety profile, with significantly lower incidences of hypotension (15.0% vs. 42.5%, P = 0.007) and respiratory depression (5.0% vs. 20.0%, P = 0.043). No significant differences were observed in secondary outcomes, including duration of mechanical ventilation, ICU length of stay, mortality, or costs.ConclusionIn mechanically ventilated, postoperative cancer patients, remimazolam provides non-inferior sedation efficacy compared to propofol, but with a significantly more favorable safety profile, particularly regarding hemodynamic and respiratory stability. These findings position Remimazolam as a promising and safer alternative for sedation in this vulnerable population.
